{"keywords":["immunotherapy","infusion management","patient safety"],"genes":["granulocyte macrophage colony stimulating factor","interleukin 2"],"publicationTypes":["Journal Article"],"abstract":"Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.","title":"Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma.","pubmedId":"27456981"}